Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STK-012 in Advanced NSCLC and Other Solid Tumors
NCT05098132Phase 2Recruiting
- Sponsor
- Synthekine
- Start
- Jan 2022
- Primary completion
- Jan 2029
- Modality
- Cytokines & Interferons
- Countries
- 6
01
Overview
A Phase 2 trial of stk-012 in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Synthekine. Started Jan 2022; status: recruiting.
02
Drugs
stk-012
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05098132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098132.